Importantly, a recent phase 1 trial demonstrated that dual PD-L1 and TGFβ blockade safely enhanced anti-tumor immunity in a cohort of patients with newly diagnosed human papilloma virus (HPV)-unrelated head and neck squamous cell carcinoma [111]. This evidence concerns the gene TGFB1 and head and neck squamous cell carcinoma.